Adrastia Biotechnology was founded in 2013 to provide a highly accurate Breast Cancer diagnostic protocol that is easy to administer, non-invasive, will deliver rapid results, and provide women with a personal health history.
Adrastia Biotechnology obtains the urine sample and runs high throughput protein quantification and targeted mRNA/microRNA sequencing to identify a pattern of breast cancer positive or negative as compared to a standard or the woman's own previous pattern. Unlike 100% genomic data, Adrastia's test results are designed to be actionable by the woman's physician and her pattern will be stored in her health record for future reference.